CMS Open Payments · Program Year 2024
GT Medical Technologies, Inc
GT Medical Technologies, Inc reported $1,759,855.19 across General Payments, Research, and Ownership to 808 physicians and teaching hospitals across 1,041 transactions.
- $1.8M
- All-tracks total
- 1,041
- Transactions
- 808
- Recipients
- +$89.8K
- General Payments vs PY2023
GT Medical Technologies, Inc reported $1,759,855.19 across all CMS Open Payments tracks (General + Research + Ownership) to 808 physicians and teaching hospitals in Program Year 2024 - ranking #481 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $345,559.39, averaging $2.2K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer gt-medical-technologies-inc GT Medical Technologies, Inc
$1.8M · #481/1,925 · 0.0% industry · PY2024
- TOT $1.8M
- RANK #481
- SHARE 0.0%
- TXN 1,041
- RCP 808
- CAT 5
- GEN $345.6K
- ΔGEN +$89.8K
- TOP1 25.2%
- PY 2024
Volume peers
Nearest volume peer: Aegis Spine, Inc. ($1.8M)
GT Medical Technologies, Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
GT Medical Technologies, Inc's CMS-reported General Payments increased by $89.8K (+35.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: GT MEDICAL TECHNOLOGIES, INCPY2023: GT MEDICAL TECHNOLOGIES, INCPY2024: GT Medical Technologies, Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $255,754.28
- PY2024
- $345,559.39
What the Data Shows for GT Medical Technologies, Inc
Rank #481 of 1,925 companies in CMS Open Payments for 2024 belongs to GT Medical Technologies, Inc, which reported $1,759,855.19 across 1,041 transactions to 808 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $1.7K per transaction and $2.2K per recipient.
The 5-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $174.8K, accounting for 50.6% of this company's General Payments and 73 transactions.
General Payment Breakdown by Type
Across 5 types of general payments, GT Medical Technologies, Inc's largest category was "Consulting Fee" at $174.8K - 50.6% of General Payments.
GT Medical Technologies, Inc reports 5 general-payment categories - the top three are Consulting Fee (50.6%), Travel and Lodging (23.0%), and Food and Beverage (16.7%). The remaining 2 categories make up 9.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How GT Medical Technologies, Inc divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $174.8K | 73 | 50.6% |
| Travel and Lodging | $79.6K | 82 | 23.0% |
| Food and Beverage | $57.7K | 639 | 16.7% |
| Honoraria | $32.4K | 13 | 9.4% |
| Compensation for Faculty or Speaker (Medical Education) | $1.1K | 1 | 0.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $172,128.95 (49.8%) of $345,559.39 in this company's General Payments records across 230 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for GT Medical Technologies, Inc
The five named recipients with the highest reported General Payments from this company
- 1
David Mccracken
$87,034.36 across 44 reported transactions
- 2
Imran Mohiuddin
$29,647.11 across 29 reported transactions
- 3
Daniel Kim
$19,936.48 across 31 reported transactions
- 4
Simon Hanft
$19,145.07 across 27 reported transactions
- 5
Matthew Shepard
$16,365.93 across 18 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as GT Medical Technologies, Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about GT Medical Technologies, Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with GT Medical Technologies, Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Amylyx Pharmaceuticals, Inc.
Medivation LLC.
Preceptis Medical, Inc.
Radiometer America, Inc
Dompe US, Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.